Year :
2021
| Month :
April
| Volume :
15
| Issue :
4
| Page :
FC14 - FC17
Full Version
Study on Synergistic Effect of Bromocriptine
and Sitagliptin in Streptozotocin-induced
Diabetic Rats
Published: April 1, 2021 | DOI: https://doi.org/10.7860/JCDR/2021/47643.14799
Govindaraj Nileshraj, Chandrasekaran Swithraa, Murugesan Sakthibalan, Maruti Shripati Sawadkar
1. Assistant Professor, Department of Pharmacology, Government Thiruvannamalai Medical College and Hospital, Thiruvannamalai, Tamil Nadu, India.
2. Assistant Professor, Department of Biochemistry, Government Thiruvannamalai Medical College and Hospital, Thiruvannamalai, Tamil Nadu, India.
3 Associate Professor, Department of Pharmacology, Sri Venkateshwara Medical College Hospital and Research Centre, Pondicherry, Pondicherry, India.
4. Professor (Retd), Department of Pharmacology, Sri Manakula Vinayagar Medical College and Hospital, Pondicherry, India.
Correspondence Address :
Dr. Govindaraj Nileshraj,
Flat F1, Sai Nivas, Sai Balaji Foundation, Siddharth Nagae, 5th Street, Nanmangalam, Chennai, Tamil Nadu, India.
E-mail: nileshgovindaraj@gmail.com
Abstract
Introduction: Diabetes mellitus is a potentially morbid condition with high prevalence worldwide. Restoration of euglycemia in type 2 diabetes mellitus is difficult to achieve due to its multifactorial pathogenesis and frequently requires multiple anti-diabetic medications with different mechanism of action. This study is based on the possible synergistic effect of Sitagliptin and Bromocriptine in reducing blood sugar in diabetic animal models.
Aim: To evaluate the effect of Sitagliptin and Bromocriptine monotherapy and their combination in three different doses on blood sugar, Lipid profile, Liver and renal parameters in diabetic albino Wistar rats.
Materials and Methods: An experimental animal study was conducted on 48 adult male albino wistar rats for a period of one month (August 2014). Streptozotocin induced (40 mg/kg IP) diabetic rats were divided into six groups of eight animals each weighing 150-200 gms. Group I- Vehicle (distilled water), Group IISitagliptin (100 mg/kg), Group III- Bromocriptine (10 mg/kg), Group IV- Sitagliptin (75 mg/kg)+Bromocriptine (7.5 mg/kg), Group V- Sitagliptin (100 mg/kg)+Bromocriptine (10 mg/kg), Group VI- Sitagliptin (125 mg/kg)+Bromocriptine (12.5 mg/kg). All drugs were given once daily (per oral) for four weeks. Body weight, fasting blood sugar, fasting lipid profile, liver parameters and renal parameters were estimated before and after administration of the drugs. Results were analysed with Statistical Package for the Social Science (SPSS) software version 16.0 using one-way ANOVA followed by post-hoc Dunnett t test, p-value <0.05 was considered statistically significant.
Results: The low dose combination therapy [Sitagliptin (75 mg/ kg)+Bromocriptine (7.5 mg/kg)] showed a significant decrease in body weight (p<0.05), fasting blood sugar (p<0.001) compared with the vehicle group. It also showed a favorable lipid profile, renal and liver parameters compared with the vehicle, monotherapy and other combination regimens.
Conclusion: The low dose combination therapy of Sitagliptin and Bromocriptine showed a better control over fasting blood sugar along with a beneficial effect on lipid profile, liver parameters and renal parameters than compared to other groups.
Keywords
Albino wistar rats, Diabetes mellitus, Drug combination, Fasting blood sugar
10.7860/JCDR/2021/47643.14799
Date of Submission: Nov 04, 2020
Date of Peer Review: Dec 28, 2020
Date of Acceptance: Jan 18, 2021
Date of Publishing: Apr 01, 2021
AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? No
• For any images presented appropriate consent has been obtained from the subjects. No
PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Nov 04, 2020
• Manual Googling: Jan 15, 2021
• iThenticate Software: Mar 31, 2021 (19%)
ETYMOLOGY: Author Origin
|